Form 4: SI-BONE Director Gregory Hinckley Reports Acquisition of Restricted Stock Units

SI-BONE, Inc. Director Gregory K. Hinckley reported the acquisition of 8,675 restricted stock units, increasing his beneficial ownership in the company.

Summary

• Gregory K. Hinckley, a Director of SI-BONE, Inc. (SIBN), reported a transaction on June 5, 2025.
• The transaction involved the acquisition of 8,675 shares of common stock through the settlement of restricted stock units (RSUs).
• These RSUs were granted at a price of $0.00, as they represent a contingent right to receive shares.
• Following this transaction, Mr. Hinckley's total beneficial ownership in SI-BONE, Inc. is 102,050 shares, which includes the newly acquired 8,675 RSUs.
• An additional 75,603 shares are held indirectly by Gregory K. Hinckley and Mary C. Hinckley as Community Property with the Right of Survivorship.
• The 8,675 restricted stock units will vest 100% upon the earlier of the next annual general meeting of stockholders or one year from the Vesting Commencement Date, contingent on Mr. Hinckley's continuous service on the Board of Directors.

Sentiment

Score: 6

Explanation: The filing is a routine insider transaction reporting an equity grant, which is generally a neutral to slightly positive event as it aligns director interests with shareholders. It contains no negative financial or operational news.

Positives

• Director Gregory K. Hinckley received 8,675 restricted stock units, aligning his interests with shareholders.
• The grant of RSUs at a $0.00 price indicates compensation for board service, which is a common practice.

Negatives

• No specific negative financial or operational information is disclosed in this Form 4 filing, as it primarily reports insider stock transactions.

Risks

• The vesting of the restricted stock units is contingent on Gregory K. Hinckley's continuous service as a member of the Company's Board of Directors, meaning forfeiture if service ceases before vesting.

Future Outlook

The vesting schedule for the restricted stock units indicates future share issuance to Director Hinckley, contingent on his continued service, aligning his long-term interests with the company's performance.

Management Comments

• No direct management comments or quotes are typically included in a Form 4 filing, which is a transactional report.

Industry Context

This Form 4 filing is a routine disclosure of insider equity compensation within the medical device industry. Such grants are common practice to incentivize and retain board members, aligning their interests with long-term shareholder value in a sector focused on innovation and regulatory compliance.

Comparison to Industry Standards

• The grant of restricted stock units to a director at a $0.00 price is a standard form of equity compensation across various industries, including medical devices.
• Companies like Medtronic (MDT), Stryker (SYK), and Zimmer Biomet (ZBH) also utilize RSU grants as part of their executive and director compensation packages to foster long-term commitment and align interests with company performance.
• The specific number of units granted would typically be benchmarked against peer companies of similar size and market capitalization within the medical device sector, though this document does not provide comparative data.

Stakeholder Impact

• Shareholders: The grant of restricted stock units to a director aligns management's interests with shareholder value creation, as the value of the units is tied to the company's stock performance.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The restricted stock units are expected to vest 100% upon the earlier of the next annual general meeting of stockholders or one year from the Vesting Commencement Date, subject to continuous service.

Key Dates

Keywords

SI-BONE, SIBN, SEC Form 4, Insider Trading, Restricted Stock Units, RSU, Beneficial Ownership, Director Compensation, Equity Grant, Medical Devices